Literature DB >> 25022512

Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle.

Lise Román Moltzau1, Jan Magnus Aronsen1, Silja Meier1, Jonas Skogestad1, Øivind Ørstavik1, Gustav B Lothe1, Ivar Sjaastad1, Tor Skomedal1, Jan-Bjørn Osnes1, Finn Olav Levy2, Eirik Qvigstad1.   

Abstract

We previously found a negative inotropic (NIR) and positive lusitropic response (LR) to C-type natriuretic peptide (CNP) in the failing heart ventricle. In this study, we investigated and compared the functional responses to the natriuretic peptides (NPs), brain (BNP) and C-type natriuretic peptide (CNP), and relate them to cGMP regulation and effects on downstream targets. Experiments were conducted in left ventricular muscle strips and ventricular cardiomyocytes from Wistar rats with heart failure 6 weeks after myocardial infarction. As opposed to CNP, BNP did not cause an NIR or LR, despite increasing cGMP levels. The BNP-induced cGMP elevation was mainly and markedly regulated by phosphodiesterase (PDE) 2 and was only marginally increased by PDE3 or PDE5 inhibition. Combined PDE2, -3, and -5 inhibition failed to reveal any functional responses to BNP, despite an extensive cGMP elevation. BNP decreased, whereas CNP increased, the amplitude of the Ca(2+) transient. BNP did not increase phospholamban (PLB) or troponin I (TnI) phosphorylation, Ca(2+) extrusion rate constant, or sarcoplasmatic reticulum Ca(2+) load, whereas CNP did. Both BNP and CNP reduced the peak of the L-type Ca(2+) current. Cyclic GMP elevations by BNP and CNP in cardiomyocytes were additive, and the presence of BNP did not alter the NIR to CNP or the CNP-induced PLB and TnI phosphorylation. However, a small increase in the LR to maximal CNP was observed in the presence of BNP. In conclusion, different responses to cGMP generated by BNP and CNP suggest different compartmentation of the cGMP signal and different roles of the two NPs in the failing heart.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25022512     DOI: 10.1124/jpet.114.214882

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

Authors:  S Jeson Sangaralingham; Paul M McKie; Tomoko Ichiki; Christopher G Scott; Denise M Heublein; Horng H Chen; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

2.  B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

Authors:  Sara J Holditch; Claire A Schreiber; Peter C Harris; Nicholas F LaRusso; Marina Ramirez-Alvarado; Alessandro Cataliotti; Vicente E Torres; Yasuhiro Ikeda
Journal:  Kidney Int       Date:  2017-04-14       Impact factor: 10.612

Review 3.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

4.  Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.

Authors:  Dan Li; Chieh-Ju Lu; Guoliang Hao; Hannah Wright; Lavinia Woodward; Kun Liu; Elisa Vergari; Nicoletta C Surdo; Neil Herring; Manuela Zaccolo; David J Paterson
Journal:  Hypertension       Date:  2015-04-27       Impact factor: 10.190

5.  C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Authors:  Tiankai Li; Heng-Jie Cheng; Nobuyuki Ohte; Hiroshi Hasegawa; Atsushi Morimoto; David M Herrington; William C Little; Weimin Li; Che Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2016-03-29       Impact factor: 4.030

Review 6.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

7.  FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons.

Authors:  Gaia Calamera; Dan Li; Andrea Hembre Ulsund; Jeong Joo Kim; Oliver C Neely; Lise Román Moltzau; Marianne Bjørnerem; David Paterson; Choel Kim; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Commun Biol       Date:  2019-10-29

Review 8.  Studying signal compartmentation in adult cardiomyocytes.

Authors:  Aleksandra Judina; Julia Gorelik; Peter T Wright
Journal:  Biochem Soc Trans       Date:  2020-02-28       Impact factor: 5.407

9.  A New Chimeric Natriuretic Peptide, CNAAC, for the Treatment of Left Ventricular Dysfunction after Myocardial Infarction.

Authors:  Shu-Miao Zhang; Hong-Lin Zhao; Xiao-Ming Gu; Juan Li; Na Feng; Yue-Min Wang; Rong Fan; Wen-Sheng Chen; Jian-Ming Pei
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

10.  Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP.

Authors:  Hariharan Subramanian; Alexander Froese; Peter Jönsson; Hannes Schmidt; Julia Gorelik; Viacheslav O Nikolaev
Journal:  Nat Commun       Date:  2018-06-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.